Previously submitted to: JMIR Cancer (no longer under consideration since Nov 19, 2025)
Date Submitted: Aug 5, 2025
Open Peer Review Period: Aug 7, 2025 - Oct 2, 2025
(closed for review but you can still tweet)
NOTE: This is an unreviewed Preprint
Warning: This is a unreviewed preprint (What is a preprint?). Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn (a note "no longer under consideration" will appear above).
Peer review me: Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period (in this case, a "Peer Review Me" button to sign up as reviewer is displayed above). All preprints currently open for review are listed here. Outside of the formal open peer-review period we encourage you to tweet about the preprint.
Citation: Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author).
Final version: If our system detects a final peer-reviewed "version of record" (VoR) published in any journal, a link to that VoR will appear below. Readers are then encourage to cite the VoR instead of this preprint.
Settings: If you are the author, you can login and change the preprint display settings, but the preprint URL/DOI is supposed to be stable and citable, so it should not be removed once posted.
Submit: To post your own preprint, simply submit to any JMIR journal, and choose the appropriate settings to expose your submitted version as preprint.
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Retinal Microvascular and Microstructural Alterations in Lung Cancer Patients Treated with Albumin-Bound Paclitaxel: A Novel OCTA Approach
ABSTRACT
Background:
Lung cancer is one of the most prevalent malignant tumors worldwide and one of the leading causes of cancer-related deaths, In the early stages, most lung cancer patients have no specific clinical signs or symptoms, which often leads to delayed diagnosis. By the time obvious symptoms appear, the disease has usually progressed to intermediate or advanced stages
Objective:
This study aimed to conduct a comprehensive investigation into the retinal microvascular and microstructural alterations, particularly retinal thickness and vascular density, in lung cancer (LC) patients treated with albumin-bound paclitaxel (ABP),and to explore their potential as biomarkers for disease monitoring and treatment evaluation.
Methods:
A total of 20 healthy controls (HCs group, 40 eyes), 20 untreated LC patients (LC group, 40 eyes), and 20 LC patients treated with ABP (ABP group, 40 eyes) were enrolled in this study.Retinal thickness and superficial vessel density (SVD) were analyzed by optical coherence tomography angiography (OCTA) in nine subregions defined by the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol.Statistical analyses included one-way ANOVA and Bonferroni correction for multiple comparisons as well as receiver operating characteristic curve analyses to compare groups and assess the diagnostic accuracy of measured parameters.
Results:
Retinal microvessel density was significantly lower in LC patients compared to HCs (p < 0.001), and further lower in patients in the ABP group (p < 0.001).ROC analysis demonstrated high diagnostic accuracy in differentiating groups based on retinal thickness and SVD (area under the curve, AUC > 0.7). Dry eye parameters, including tear break-up time (tBUT), Schirmer test (SIT), and tear meniscus height (TMH), were significantly impaired in both the LC and ABP groups compared to HCs (p < 0.001), with no significant improvement observed after ABP treatment.
Conclusions:
OCTA is effective in detecting retinal microvascular changes in LC patients that are exacerbated by ABP treatment. These findings suggest that retinal changes can be used as an adjunctive biomarker to monitor disease progression and treatment-related toxicity in patients with LC.
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.